# OS-151

Source: https://onco.cc/drugs/os-151/  
OnCo record `os-151` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OS-151 is an experimental modified BCG from OncoSTING for bladder cancer, built to release an immune-activating molecule. It is in laboratory testing.

## Summary

OS-151 is the lead product of OncoSTING, a second-generation BCG for non-muscle invasive bladder cancer that produces a STING agonist; the NIH RePORTER abstract describes the strain as overexpressing c-di-AMP. OncoSTING also plans intratumoral use in other solid tumours. Evidence is preclinical.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: rBCG-STING
- Tags: pipeline
- Code: OS-151
- Modality: Recombinant BCG immunotherapy
- Mechanism: A recombinant Bacillus Calmette-Guerin strain that overexpresses c-di-AMP, a STING agonist, to add STING-driven innate immune activation to BCG's effect, as the developer's award abstract describes.

## Sources

- OncoSTING: technology: https://www.oncosting.com/technology
- NIH RePORTER: SBIR award 1R44CA310037-01: https://reporter.nih.gov/project-details/11312959

## Connected records

- technologies: [STING & innate immune agonists](https://onco.cc/technologies/sting-agonist/)
- companies: [OncoSTING](https://onco.cc/companies/oncosting/)

---
JSON: https://onco.cc/api/v1/entities/os-151.json